Program
Diclofenac Sodium Gel
Also written as “Diclofenac sodium gel 1%”, “Voltaren Gel” and “Diclofenac sodium gel”.
Its studies are mostly in Keratosis, Actinic · Osteoarthritis, Knee · Osteoarthritis · Pain · Myalgia, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 30 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Amzell | 20 open or running | phase 1since Jul 7, 2023 | Jul 7, 2023 | none ahead |
| Akorn | 10 open or running | phase 3since Sep 22, 2016 | Sep 22, 2016 | none ahead |
| Encube Ethicals Pvt. | 10 open or running | phase 3since Jan 30, 2019 | Jan 30, 2019 | none ahead |
| Glenmark Pharmaceuticals Ltd. India | 10 open or running | phase 3since Nov 3, 2015 | Nov 3, 2015 | none ahead |
| HALEON | 10 open or running | phase 4since Apr 18, 2024 | Apr 18, 2024 | none ahead |
| Sun Pharmaceutical Industries | 10 open or running | phase 1since Dec 3, 2012 | Dec 3, 2012 | none ahead |
| Viatris | 10 open or running | phase 3since May 30, 2017 | May 30, 2017 | none ahead |
Also a collaborator on its studies: Novum Pharmaceutical Research Services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2005First study: phase 3 study in OsteoarthritisNew to NovartisNovartis · NCT00171652 · 360 enrolled · France, Germany
- Jan 24, 2007Phase 3 study in Osteoarthritis, KneeNovartis · NCT00426621 · 420 enrolled · United States
- Dec 3, 2012Sun Pharmaceutical Industries’ first study: phase 1 study in Keratosis, ActinicNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT01742663 · 435 enrolled
- Oct 20, 2014Phase 3 study in MyalgiaNovartis · NCT02271854 · 102 enrolled · United States
- Nov 3, 2015Glenmark Pharmaceuticals Ltd. India’s first study: phase 3 study in OsteoarthritisNew to Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals Ltd. India · NCT02596451 · 1,164 enrolled · United States
- Sep 22, 2016Akorn’s first study: phase 3 study in Osteoarthritis, KneeNew to AkornAkorn · NCT02913521 · 934 enrolled · Estonia, Latvia, Lithuania and more
- May 30, 2017Viatris’s first study: phase 3 study in Osteoarthritis, KneeNew to ViatrisViatris · NCT03172780 · 1,220 enrolled · India
- Jan 30, 2019Encube Ethicals Pvt.’s first study: phase 3 study in Keratosis, ActinicNew to Encube Ethicals Pvt.Encube Ethicals Pvt. · NCT03826550 · 655 enrolled · United States
- Jul 7, 2023Amzell’s first study: phase 1 study in HealthyNew to AmzellAmzell · NCT05968482 · 74 enrolled · United States
- Apr 18, 2024HALEON’s first study: phase 4 study in PainNew to HALEONHALEON · NCT06379893 · 196 enrolled · United States, Poland
- Dec 6, 2024Phase 1 study in Healthy VolunteerAmzell · NCT06729073 · 34 enrolled · Germany
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06729073Healthy Volunteer · Germany | 1 | Completed | Amzell | Jun 10, 2025 | 34 |
| NCT06379893Pain · United States, Poland | 4 | Completed | HALEON | Oct 29, 2024 | 196 |
| NCT05968482Healthy · United States | 1 | Completed | Amzell | Dec 27, 2023 | 74 |
| NCT03826550Keratosis, Actinic · United States | 3 | Completed | Encube Ethicals Pvt. | Jun 30, 2018 | 655 |
| NCT03172780Osteoarthritis, Knee · India | 3 | Completed | Viatris | Dec 5, 2017 | 1,220 |
| NCT02913521Osteoarthritis, Knee · Estonia, Latvia, Lithuania and more | 3 | Completed | Akorn | Apr 2016 | 934 |
| NCT02596451Osteoarthritis · United States | 3 | Completed | Glenmark Pharmaceuticals Ltd. India | Mar 2016 | 1,164 |
| NCT02271854Myalgia · United States | 3 | Completed | Novartis | Dec 2014 | 102 |
| NCT01742663Keratosis, Actinic | 1 | Completed | Sun Pharmaceutical Industries | Jul 2013 | 435 |
| NCT00426621Osteoarthritis, Knee · United States | 3 | Completed | Novartis | 420 | |
| NCT00171652Osteoarthritis · France, Germany | 3 | Completed | Novartis | 360 |
How it is read
Names in the registry
- “Diclofenac Sodium Gel”, 3 entries
- “Diclofenac sodium gel 1%”, 3 entries
- “Voltaren Gel”, 1 entry
- “Diclofenac sodium gel”, 1 entry
- “Diclofenac sodium gel 3%”, 1 entry
Conditions, from the studies’ own filings
- Keratosis, Actinic, 3 studies
- Osteoarthritis, Knee, 3 studies
- Osteoarthritis, 2 studies
- Pain, 1 study
- Myalgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.